Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
<!-- Name:DistributionId Value:8837590 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:VOR
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable…
<!-- Name:DistributionId Value:8750375 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for…
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia…